Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM: Ad5FGF-4 Gene Therapy for Refractory Angina
NCT02928094Phase 3Unknown
- Sponsor
- Angionetics, Inc.
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
01
Overview
Phase 3, randomised, double-blind trial in Angina Pectoris (AP) comparing Generx (Ad5FGF-4) with Placebo (2 arms). Primary endpoint: Exercise Tolerance Test duration at Month 6. Status: unknown.
02
Drugs
alferminogene tadenovec
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT02928094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928094.